PPAR-targeted therapies in the field of NAFLD and NASH have demonstrated pleiotropic beneficial effects, both on NAFLD-specific outcomes as well as on a multitude of metabolic functions. This evidence concerns the gene PPARA and metabolic dysfunction-associated steatotic liver disease.